ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
November 25, 2019 at 07:00 am EST
ArQule, Inc. announced that final clinical data from the company-sponsored phase 1 study of ARQ 531 will be presented on December 9, 2019 at the 61stAmerican Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The poster presentation will highlight the final data set with respect to ARQ 531’s safety profile, clinical activity and durability across multiple refractory B-cell malignancies, including C481-mutant chronic lymphocytic leukemia (CLL).